{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:25:03Z","timestamp":1765887903555},"reference-count":102,"publisher":"Ubiquity Press, Ltd.","issue":"3","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["gh"],"DOI":"10.1016\/j.gheart.2017.03.002","type":"journal-article","created":{"date-parts":[[2017,7,29]],"date-time":"2017-07-29T22:30:51Z","timestamp":1501367451000},"page":"179","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["World Heart Federation Cholesterol Roadmap"],"prefix":"10.5334","volume":"12","author":[{"given":"Adrianna","family":"Murphy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose R.","family":"Faria-Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Al-Rasadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Blom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberico","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ada","family":"Cuevas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Lopez-Jimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Perel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raul","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan","family":"Sniderman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rody","family":"Sy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salim","family":"Yusuf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3285","published-online":{"date-parts":[[2017,9,1]]},"reference":[{"key":"10.1016\/j.gheart.2017.03.002_bib2","series-title":"Global Action Plan for the Prevention and Control of NCDs","year":"2013"},{"key":"10.1016\/j.gheart.2017.03.002_bib3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.gheart.2015.04.003","article-title":"Reducing premature cardiovascular morbidity and mortality in people with atherosclerotic vascular disease: the World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease","volume":"10","author":"Perel","year":"2015","journal-title":"Glob Heart"},{"key":"10.1016\/j.gheart.2017.03.002_bib4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.gheart.2015.04.007","article-title":"Reducing cardiovascular mortality through tobacco control: a World Heart Federation Roadmap","volume":"10","author":"Grainger Gasser","year":"2015","journal-title":"Glob Heart"},{"key":"10.1016\/j.gheart.2017.03.002_bib5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.gheart.2015.04.006","article-title":"Reducing cardiovascular mortality through prevention and management of raised blood pressure: a World Heart Federation Roadmap","volume":"10","author":"Adler","year":"2015","journal-title":"Glob Heart"},{"key":"10.1016\/j.gheart.2017.03.002_bib6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.gheart.2016.12.001","article-title":"The WHF Roadmap for reducing CV morbidity and mortality through prevention and control of RHD","volume":"12","author":"Palafox","year":"2017","journal-title":"Glob Heart"},{"key":"10.1016\/j.gheart.2017.03.002_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.gheart.2017.01.015","article-title":"The Word Heart Federation Roadmap for nonvalvular atrial fibrill, 7tion","author":"Murphy","year":"2017","journal-title":"Glob Heart"},{"key":"10.1016\/j.gheart.2017.03.002_bib8","series-title":"Global Atlas on Cardiovascular Disease Prevention and Control","author":"Mendis","year":"2011"},{"key":"10.1016\/j.gheart.2017.03.002_bib9","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.gheart.2017.03.002_bib10","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0140-6736(10)60834-3","article-title":"Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study","volume":"376","author":"O'Donnell","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.gheart.2017.03.002_bib11","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0140-6736(10)62038-7","article-title":"National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants","volume":"377","author":"Farzadfar","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.gheart.2017.03.002_bib12","unstructured":"Imperial College, Environment and Global Health Research Group. Mean Age-Standardized Cholesterol, mmol\/L. Available at: http:\/\/wwwf.imperial.ac.uk\/medicine\/apps\/ezzati\/metabolic_risks\/cholesterol\/. Accessed January 22, 2017."},{"key":"10.1016\/j.gheart.2017.03.002_bib13","series-title":"Prevention of Cardiovascular Disease: Guidelines for Assessment and Management of Cardiovascular Risk","year":"2007"},{"key":"10.1016\/j.gheart.2017.03.002_bib14","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/HJH.0b013e3282861fd3","article-title":"World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries","volume":"25","author":"Mendis","year":"2007","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.gheart.2017.03.002_bib15","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(08)60418-3","article-title":"Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I follow-up study cohort","volume":"371","author":"Gaziano","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.gheart.2017.03.002_bib16","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(03)12655-4","article-title":"Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk","volume":"361","author":"Murray","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.gheart.2017.03.002_bib17","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1311890","article-title":"Cardiovascular risk and events in 17 low-, middle-, and high-income countries","volume":"371","author":"Yusuf","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gheart.2017.03.002_bib18","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","article-title":"Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths","volume":"370","author":"Lewington","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.gheart.2017.03.002_bib19","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.atherosclerosis.2016.08.018","volume":"253","author":"Catapano","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.gheart.2017.03.002_bib20","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa020194","article-title":"Effects of the amount and intensity of exercise on plasma lipoproteins","volume":"347","author":"Kraus","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.gheart.2017.03.002_bib21","first-page":"CD011737","article-title":"Reduction in saturated fat intake for cardiovascular disease","author":"Hooper","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 2","key":"10.1016\/j.gheart.2017.03.002_bib22","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1038\/sj.ejcn.1602973","article-title":"Health effects of trans-fatty acids: experimental and observational evidence","volume":"63","author":"Mozaffarian","year":"2009","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.gheart.2017.03.002_bib23","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.gheart.2017.03.002_bib24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1161\/CIRCULATIONAHA.115.018585","article-title":"Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: a comprehensive review","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.gheart.2017.03.002_bib25","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.jacc.2015.07.050","article-title":"Food consumption and its impact on cardiovascular disease: importance of solutions focused on the globalized food system: a report from the workshop convened by the World Heart Federation","volume":"66","author":"Anand","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.gheart.2017.03.002_bib26","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study","volume":"117","author":"D'Agostino","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.gheart.2017.03.002_bib27","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"Perk","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.gheart.2017.03.002_bib28","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/eurheartj\/ehu107","article-title":"The ACC\/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC\/EAS guidelines for the management of dyslipidaemias 2011","volume":"35","author":"Ray","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.gheart.2017.03.002_bib29","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","article-title":"Cholesterol lowering in intermediate-risk persons without cardiovascular disease","volume":"374","author":"Yusuf","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gheart.2017.03.002_bib30","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.gheart.2017.03.002_bib31","unstructured":"UK National Health Service. NHS Health Check: Your NHS Health Check Guide. London, UK: NHS. Available at: http:\/\/www.nhs.uk\/Conditions\/nhs-health-check\/Pages\/What-is-an-NHS-Health-Check.aspx. Accessed August 12, 2016."},{"issue":"1","key":"10.1016\/j.gheart.2017.03.002_bib32","first-page":"CD010411","article-title":"Systematic versus opportunistic risk assessment for the primary prevention of cardiovascular disease","author":"Dyakova","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.gheart.2017.03.002_bib33","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Goff","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.gheart.2017.03.002_bib34","series-title":"Prevention of cardiovascular Disease: Pocket Guidelines for Assessment and Management of Cardiovascular Risk (WHO\/ISH Cardiovascular Risk Prediction Charts for WHO Epidemiological Sub-Regions AFR D and AFR E)","year":"2007"},{"key":"10.1016\/j.gheart.2017.03.002_bib35","series-title":"Tietz Textbook of Clinical Chemistry and Molecular Diagnostics","first-page":"903","article-title":"Lipids, lipoproteins, apolipoproteins, and other cardiovascular risk factors","author":"Rifai","year":"2006"},{"key":"10.1016\/j.gheart.2017.03.002_bib36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cca.2013.11.008","article-title":"Standardization of collection requirements for fasting samples: for the Working Group on Preanalytical Phase (WG-PA) of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)","volume":"432","author":"Simundic","year":"2014","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.gheart.2017.03.002_bib37","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1093\/eurheartj\/ehw152","volume":"37","author":"Nordestgaard","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.gheart.2017.03.002_bib38","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrcardio.2015.28","article-title":"Cardiovascular risk assessment: a global perspective","volume":"12","author":"Zhao","year":"2015","journal-title":"Nat Rev Cardiol"},{"issue":"Suppl 3","key":"10.1016\/j.gheart.2017.03.002_bib39","doi-asserted-by":"crossref","first-page":"S353","DOI":"10.1093\/infdis\/jis202","article-title":"Metabolic and cardiovascular complications in HIV-infected patients: new challenges for a new age","volume":"205","author":"Gandhi","year":"2012","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.gheart.2017.03.002_bib40","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/eurheartj\/ehq448","article-title":"Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score","volume":"32","author":"McGorrian","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.gheart.2017.03.002_bib41","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S2213-8587(15)00081-9","article-title":"A\u00a0novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys","volume":"3","author":"Hajifathalian","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.gheart.2017.03.002_bib42","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1093\/eurheartj\/ehv251","article-title":"The high-density lipoprotein-adjusted SCORE model worsens SCORE-based risk classification in a contemporary population of 30,824 Europeans: the Copenhagen General Population Study","volume":"36","author":"Mortensen","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.gheart.2017.03.002_bib43","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1001\/jamacardio.2016.0991","article-title":"Risk of premature cardiovascular disease vs the number of premature cardiovascular events","volume":"1","author":"Sniderman","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.gheart.2017.03.002_bib44","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJMoa1315665","article-title":"Application of new cholesterol guidelines to a population-based sample","volume":"370","author":"Pencina","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gheart.2017.03.002_bib45","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1161\/CIRCULATIONAHA.115.018383","article-title":"Individualized statin benefit for determining statin eligibility in the primary prevention of cardiovascular disease","volume":"133","author":"Thanassoulis","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.gheart.2017.03.002_bib46","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.gheart.2017.03.002_bib47","first-page":"CD004816","article-title":"Statins for the primary prevention of cardiovascular disease","author":"Taylor","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.gheart.2017.03.002_bib48","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.gheart.2017.03.002_bib49","series-title":"Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease","year":"2015"},{"key":"10.1016\/j.gheart.2017.03.002_bib50","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.gheart.2017.03.002_bib51","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gheart.2017.03.002_bib52","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehw480","article-title":"European Society of Cardiology\/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin\/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk","author":"Landmesser","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.gheart.2017.03.002_bib53","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","volume":"68","author":"Lloyd-Jones","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.gheart.2017.03.002_bib54","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gheart.2017.03.002_bib55","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/M14-2957","article-title":"Effects of proprotein convertase subtilisin\/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis","volume":"163","author":"Navarese","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gheart.2017.03.002_bib56","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.gheart.2017.03.002_bib57","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","article-title":"Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial","volume":"168","author":"Schwartz","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.gheart.2017.03.002_bib58","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.gheart.2017.03.002_bib59","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","article-title":"AHA\/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation","volume":"124","author":"Smith","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.gheart.2017.03.002_bib60","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"Perk","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.gheart.2017.03.002_bib61","series-title":"Prevention of Recurrent Heart Attacks and Strokes in Low- and Middle-Income Populations: Evidence-Based Recommendations for Policy-Makers and Health Professionals","year":"2003"},{"key":"10.1016\/j.gheart.2017.03.002_bib62","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijcard.2013.11.025","article-title":"Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation","volume":"171","author":"Watts","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.gheart.2017.03.002_bib63","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.gheart.2017.03.002_bib64","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1210\/jc.2012-1563","article-title":"Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication","volume":"97","author":"Benn","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.gheart.2017.03.002_bib65","series-title":"Variation in the Prevalence of Familial Hypercholesterolemia Around the World","author":"Mathews","year":"2015"},{"key":"10.1016\/j.gheart.2017.03.002_bib66","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1136\/jmg.2006.038356","article-title":"Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk","volume":"43","author":"Humphries","year":"2006","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.gheart.2017.03.002_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta4290","article-title":"Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis","volume":"4","author":"Marks","year":"2000","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.gheart.2017.03.002_bib68","series-title":"GeneReviews(R)","article-title":"Familial hypercholesterolemia","author":"Youngblom","year":"1993"},{"key":"10.1016\/j.gheart.2017.03.002_bib69","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","article-title":"The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association","volume":"132","author":"Gidding","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.gheart.2017.03.002_bib70","doi-asserted-by":"crossref","first-page":"e1311","DOI":"10.1542\/peds.2011-2903","article-title":"Developing the 2011 integrated pediatric guidelines for cardiovascular risk reduction","volume":"129","author":"Gidding","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.gheart.2017.03.002_bib71","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1136\/bmj.324.7349.1303","article-title":"Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia","volume":"324","author":"Marks","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.gheart.2017.03.002_bib72","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/MOL.0000000000000365","article-title":"Challenges in the health economics of familial hypercholesterolemia","volume":"27","author":"Norman","year":"2016","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.gheart.2017.03.002_bib73","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1186\/1471-2458-14-1177","article-title":"Prevalence of hypertension and associated cardiovascular risk factors in an urban slum in Nairobi, Kenya: a population-based survey","volume":"14","author":"Joshi","year":"2014","journal-title":"BMC Public Health"},{"key":"10.1016\/j.gheart.2017.03.002_bib74","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cpcardiol.2009.10.002","article-title":"Growing epidemic of coronary heart disease in low- and middle-income countries","volume":"35","author":"Gaziano","year":"2010","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.gheart.2017.03.002_bib75","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2471\/BLT.10.079947","article-title":"High total serum cholesterol, medication coverage and therapeutic control: an analysis of national health examination survey data from eight countries","volume":"89","author":"Roth","year":"2011","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.gheart.2017.03.002_bib76","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.annepidem.2007.01.032","article-title":"Trends in ATP-III-defined high blood cholesterol prevalence, awareness, treatment and control among U.S. adults","volume":"17","author":"Hyre","year":"2007","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.gheart.2017.03.002_bib77","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1186\/s12889-015-1709-2","article-title":"Prevalence of cardiovascular disease risk factors among a Nigerian adult population: relationship with income level and accessibility to CVD risks screening","volume":"15","author":"Oguoma","year":"2015","journal-title":"BMC Public Health"},{"key":"10.1016\/j.gheart.2017.03.002_bib78","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jacl.2015.12.029","article-title":"Prevalence, awareness, treatment, and control of high low-density lipoprotein cholesterol in Brazil: baseline of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)","volume":"10","author":"Lotufo","year":"2016","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.gheart.2017.03.002_bib79","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/2047487315569401","article-title":"EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries","volume":"23","author":"Kotseva","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.gheart.2017.03.002_bib80","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(11)61215-4","article-title":"Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey","volume":"378","author":"Yusuf","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.gheart.2017.03.002_bib81","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.atherosclerosis.2015.04.809","article-title":"Prevalence and management of familial hypercholesterolaemia in coronary patients: an analysis of EUROASPIRE IV, a study of the European Society of Cardiology","volume":"241","author":"De Backer","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.gheart.2017.03.002_bib82","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2003.11.010","article-title":"Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia","volume":"173","author":"Civeira","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.gheart.2017.03.002_bib83","doi-asserted-by":"crossref","first-page":"e000438","DOI":"10.1136\/openhrt-2016-000438","article-title":"Health system barriers and facilitators to medication adherence for the secondary prevention of cardiovascular disease: a systematic review","volume":"3","author":"Banerjee","year":"2016","journal-title":"Open Heart"},{"key":"10.1016\/j.gheart.2017.03.002_bib84","first-page":"A123","article-title":"Lifestyle interventions for hypertension and dyslipidemia among women of reproductive age","volume":"8","author":"Robbins","year":"2011","journal-title":"Prev Chronic Dis"},{"key":"10.1016\/j.gheart.2017.03.002_bib85","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(15)00469-9","article-title":"Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data","volume":"387","author":"Khatib","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.gheart.2017.03.002_bib86","first-page":"45","article-title":"How patient cost-sharing trends affect adherence and outcomes: a literature review","volume":"37","author":"Eaddy","year":"2012","journal-title":"P\u00a0T"},{"key":"10.1016\/j.gheart.2017.03.002_bib87","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s11606-011-1825-3","article-title":"A\u00a0systematic review of adherence to cardiovascular medications in resource-limited settings","volume":"26","author":"Bowry","year":"2011","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.gheart.2017.03.002_bib88","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ijcard.2016.05.066","article-title":"Socioeconomic inequalities in access to treatment for coronary heart disease: a systematic review","volume":"219","author":"Schroder","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.gheart.2017.03.002_bib89","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/j.1525-1497.2006.00530.x","article-title":"Impact of health literacy on socioeconomic and racial differences in health in an elderly population","volume":"21","author":"Howard","year":"2006","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.gheart.2017.03.002_bib90","series-title":"Perceptions of Statins: Research With Patients, GPs and Cardiologists","author":"Bohan","year":"2016"},{"key":"10.1016\/j.gheart.2017.03.002_bib91","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0140-6736(16)31532-X","article-title":"Why do people not take life-saving medications? The case of statins","volume":"388","author":"Yusuf","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.gheart.2017.03.002_bib92","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1473-3099(13)70250-0","article-title":"Diagnostic point-of-care tests in resource-limited settings","volume":"14","author":"Drain","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.gheart.2017.03.002_bib93","doi-asserted-by":"crossref","first-page":"122","DOI":"10.5694\/j.1326-5377.1988.tb120533.x","article-title":"How accurately does the Reflotron dry-chemistry system measure plasma total cholesterol levels when used a community-screening device","volume":"149","author":"Phillips","year":"1988","journal-title":"Med J Aust"},{"key":"10.1016\/j.gheart.2017.03.002_bib94","doi-asserted-by":"crossref","first-page":"e224","DOI":"10.3399\/bjgp12X630241","article-title":"Point-of-care testing for the analysis of lipid panels: primary care diagnostic technology update","volume":"62","author":"Pluddemann","year":"2012","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.gheart.2017.03.002_bib95","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.trsl.2008.11.010","article-title":"Point-of-care testing of cholesterol and triglycerides for epidemiologic studies: evaluation of the multicare-in system","volume":"153","author":"Rapi","year":"2009","journal-title":"Transl Res"},{"key":"10.1016\/j.gheart.2017.03.002_bib96","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0140-6736(08)61762-6","article-title":"Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis","volume":"373","author":"Cameron","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.gheart.2017.03.002_bib97","series-title":"Pharmaceutical Tariffs: What Is Their Effect on Prices, Protection of Local Industry and Revenue Generation?","author":"Olcay","year":"2005"},{"key":"10.1016\/j.gheart.2017.03.002_bib98","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/14737167.2.1.43","article-title":"Pharmaceutical pricing in the developing world: issues of access to medicines","volume":"2","author":"Mrazek","year":"2002","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.gheart.2017.03.002_bib99","series-title":"WHO Medicines Strategy: Framework for Action in Essential Drugs and Medicines Policy","year":"2000"},{"key":"10.1016\/j.gheart.2017.03.002_bib100","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/heapol\/czp039","article-title":"\u201cThis body does not want free medicines\u201d: South African consumer perceptions of drug quality","volume":"25","author":"Patel","year":"2010","journal-title":"Health Policy Plan"},{"key":"10.1016\/j.gheart.2017.03.002_bib101","series-title":"South Africa 2015 Stock Outs Survey","year":"2015"},{"key":"10.1016\/j.gheart.2017.03.002_bib102","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2458-14-28","article-title":"Efficacy of a text messaging (SMS) based intervention for adults with hypertension: protocol for the StAR (SMS Text-message Adherence suppoRt trial) randomised controlled trial","volume":"14","author":"Bobrow","year":"2014","journal-title":"BMC Public Health"},{"key":"10.1016\/j.gheart.2017.03.002_bib103","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.gheart.2015.04.004","article-title":"Adapting the World Heart Federation Roadmaps at the national level: next steps and conclusions","volume":"10","author":"Perel","year":"2015","journal-title":"Glob Heart"}],"container-title":["Global Heart"],"original-title":[],"link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211816017300200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211816017300200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/doi.org\/10.1016\/j.gheart.2017.03.002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T12:49:45Z","timestamp":1657543785000},"score":1,"resource":{"primary":{"URL":"https:\/\/globalheartjournal.com\/article\/10.1016\/j.gheart.2017.03.002\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,1]]},"references-count":102,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,9,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.gheart.2017.03.002","relation":{},"ISSN":["2211-8179","2211-8160"],"issn-type":[{"value":"2211-8179","type":"electronic"},{"value":"2211-8160","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"World Heart Federation Cholesterol Roadmap","name":"articletitle","label":"Article Title"},{"value":"Global Heart","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gheart.2017.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 World Heart Federation (Geneva). Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}